Bio-Thera Out-Licenses Golimumab To Russia And CIS

Represents Foray Into ‘Important Market’

 
• By Dean Rudge
  
Russia_Night
Pharmapark will leverage its strong local presence, sales and marketing capabilities, Bio-Thera said • Source: Shutterstock

More from Biosimilars

More from Products